Behavioral deficits are accompanied by immunological and neurochemical changes in a mouse model for neuropsychiatric lupus (NP-SLE)

International Journal of Molecular Sciences

Volumn 16, Issue 7, 2015, Pages 15150-15171

  Li, Yan ^a   Eskelund, Amanda R ^a,b   Zhou, Hua ^a   Budac, David P ^a   Sánchez, Connie ^a   Gulinello, Maria ^c  

^a LUNDBECK RESEARCH USA   (United States)

^b AARHUS UNIVERSITY   (Denmark)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

3 dioxygenase (IDO); Anhedonia; Chemokines; Cytokines; Forced swim test; Indoleamine 2; Kynurenine; Lupus; MRL lpr; Novel object placement test

Indexed keywords

GAMMA INTERFERON; HAPTOGLOBIN; INTERLEUKIN 10; KYNURENINE; LYMPHOTACTIN; MONOCYTE CHEMOTACTIC PROTEIN; N METHYL DEXTRO ASPARTIC ACID; SEROTONIN; CHEMOKINE; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DEPTH PERCEPTION; ENZYME ACTIVITY; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; INFLAMMATION; LIQUID CHROMATOGRAPHY; MEMORY CONSOLIDATION; MOUSE; NEUROCHEMISTRY; NEUROPSYCHIATRIC LUPUS; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TANDEM MASS SPECTROMETRY; ANIMAL; ANIMAL BEHAVIOR; BRAIN CORTEX; BRAIN VASCULITIS; C57BL MOUSE; GENETICS; HIPPOCAMPUS; IMMUNOLOGY; MEMORY; METABOLISM; PATHOPHYSIOLOGY;

MURINAE; MUS;

ANIMALS; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; CHEMOKINES; CYTOKINES; HIPPOCAMPUS; KYNURENINE; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MEMORY; MICE; MICE, INBRED C57BL;

EID: 84936876686     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160715150     Document Type: Article

References (120)

1. Ainiala, H.; Loukkola, J.; Peltola, J.; Korpela, M.; Hietaharju, A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001, 57, 496-500.
2. Steup-Beekman, G.M.; Zirkzee, E.J.; Cohen, D.; Gahrmann, B.M.; Emmer, B.J.; Steens, S.C.; Bollen, E.L.; van Buchem, M.A.; Huizinga, T.W. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: Epidemiology and radiology pointing to an immune-mediated cause. Ann. Rheum. Dis. 2013, 72, ii76-ii79.
3. Gulinello, M.; Wen, J.; Putterman, C. Neuropsychiatric Symptoms in Lupus. Psychiatr. Ann. 2012, 42, 322-328.
4. Putterman, C.; Naparstek, Y. Neuropsychiatric involvement in systemic lupus erythematosus. Isr. J. Med. Sci. 1992, 28, 458-460.
5. Stock, A.D.; Wen, J.; Putterman, C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front. Immunol. 2013, 4, 484.
6. Wen, J.; Xia, Y.; Stock, A.; Michaelson, J.S.; Burkly, L.C.; Gulinello, M.; Putterman, C. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. J. Autoimmun. 2013, 43, 44-54.
7. Carbotte, R.M.; Denburg, S.D.; Denburg, J.A. Cognitive dysfunction in systemic lupus erythematosus is independent of active disease. J. Rheumatol. 1995, 22, 863-867.
8. Kasitanon, N.; Louthrenoo, W.; Piyasirisilp, S.; Sukitawu, W.; Wichainun, R. Neuropsychiatric manifestations in Thai patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2002, 61, 96.
9. Gao, H.X.; Campbell, S.R.; Cui, M.H.; Zong, P.; Hee-Hwang, J.; Gulinello, M.; Putterman, C. Depression is an early disease manifestation in lupus-prone MRL/lpr mice. J. Neuroimmunol. 2009, 207, 45-56.
10. Ballok, D.A.; Ma, X.; Denburg, J.A.; Arsenault, L.; Sakic, B. Ibuprofen fails to prevent brain pathology in a model of neuropsychiatric lupus. J. Rheumatol. 2006, 33, 2199-2213.
11. Gao, H.X.; Sanders, E.; Tieng, A.T.; Putterman, C. Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice. J. Neuroimmunol. 2010, 229, 112-122.
12. Gulinello, M.; Putterman, C. The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus. J. Biomed. Biotechnol. 2011, 2011, doi:10.1155/2011/207504.
13. Szechtman, H.; Sakic, B.; Denburg, J.A. Behaviour of MRL mice: An animal model of disturbed behavior in systemic autoimmune disease. Lupus 1997, 6, 223-229.
14. Williams, S.; Sakic, B.; Hoffman, S.A. Circulating brain-reactive autoantibodies and behavioral deficits in the MRL model of CNS lupus. J. Neuroimmunol. 2010, 218, 73-82.
15. Wen, J.; Stock, A.; Wang, H.W.; Shlomchik, M.; Gulinello, M.; Putterman, C. Hold the rituximab: Neuropsychiatric disease in murine lupus is not B-cell dependent. Arthritis Rheum. 2013, 65, S244.
16. Wen, J.; Stock, A.; Wang, H.W.; Shlomchik, M.; Gulinello, M.; Putterman, C. Neuropsychiatric lupus is substantially unaffected by B-cell deficiency. Arthritis Rheum. 2014, 66, S855.
17. Alleva, D.G.; Kaser, S.B.; Beller, D.I. Aberrant cytokine expression and autocrine regulation characterize macrophages from young MRL+/+ and NZB/W F1 lupus-prone mice. J. Immunol. 1997, 159, 5610-5619.
18. Balomenos, D.; Rumold, R.; Theofilopoulos, A.N. Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Investig. 1998, 101, 364-371.
19. Boswell, J.M.; Yui, M.A.; Endres, S.; Burt, D.W.; Kelley, V.E. Novel and enhanced IL-1 gene expression in autoimmune mice with lupus. J. Immunol. 1988, 141, 118-124.
20. Braun, D.; Geraldes, P.; Demengeot, J. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 2003, 20, 15-25.
21. Esfandiari, E.; McInnes, I.B.; Lindop, G.; Huang, F.P.; Field, M.; Komai-Koma, M.; Wei, X.; Liew, F.Y. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J. Immunol. 2001, 167, 5338-5347.
22. Koh, J.S.; Wang, Z.; Levine, J.S. Cytokine dysregulation induced by apoptotic cells is a shared characteristic of murine lupus. J. Immunol. 2000, 165, 4190-4201.
23. Allison, D.J.; Ditor, D.S. The common inflammatory etiology of depression and cognitive impairment: A therapeutic target. J. Neuroinflamm. 2014, 11, 151.
24. Prendergast, G.C.; Metz, R.; Muller, A.J.; Merlo, L.M.; Mandik-Nayak, L. IDO2 in immunomodulation and autoimmune disease. Front. Immunol. 2014, 5, 585.
25. Postal, M.; Appenzeller, S. The importance of cytokines and autoantibodies in depression. Autoimmun. Rev. 2015, 14, 30-35.
26. Pertovaara, M.; Hasan, T.; Raitala, A.; Oja, S.S.; Yli-Kerttula, U.; Korpela, M.; Hurme, M. Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin. Exp. Immunol. 2007, 150, 274-278.
27. Widner, B.; Sepp, N.; Kowald, E.; Kind, S.; Schmuth, M.; Fuchs, D. Degradation of tryptophan in patients with systemic lupus erythematosus. Adv. Exp. Med. Biol. 1999, 467, 571-577.
28. Widner, B.; Sepp, N.; Kowald, E.; Ortner, U.; Wirleitner, B.; Fritsch, P.; Baier-Bitterlich, G.; Fuchs, D. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 2000, 201, 621-630.
29. Capuron, L.; Dantzer, R. Cytokines and depression: The need for a new paradigm. Brain Behav. Immun. 2003, 17, S119-S124.
30. Merlo, L.M.; Pigott, E.; DuHadaway, J.B.; Grabler, S.; Metz, R.; Prendergast, G.C.; Mandik-Nayak, L. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J. Immunol. 2014, 192, 2082-2090.
31. Frenois, F.; Moreau, M.; O’Connor, J.; Lawson, M.; Micon, C.; Lestage, J.; Kelley, K.W.; Dantzer, R.; Castanon, N. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32, 516-531.
32. Kennedy, P.J.; Clarke, G.; O’Neill, A.; Groeger, J.A.; Quigley, E.M.; Shanahan, F.; Cryan, J.F.; Dinan, T.G. Cognitive performance in irritable bowel syndrome: Evidence of a stress-related impairment in visuospatial memory. Psychol. Med. 2014, 44, 1553-1566.
33. O’Connor, J.C.; Andre, C.; Wang, Y.; Lawson, M.A.; Szegedi, S.S.; Lestage, J.; Castanon, N.; Kelley, K.W.; Dantzer, R. Interferon-γ and tumor necrosis factor-α mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J. Neurosci. 2009, 29, 4200-4209.
34. O’Connor, J.C.; Lawson, M.A.; Andre, C.; Briley, E.M.; Szegedi, S.S.; Lestage, J.; Castanon, N.; Herkenham, M.; Dantzer, R.; Kelley, K.W. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J. Immunol. 2009, 182, 3202-3212.
35. O’Connor, J.C.; Lawson, M.A.; Andre, C.; Moreau, M.; Lestage, J.; Castanon, N.; Kelley, K.W.; Dantzer, R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14, 511-522.
36. Too, L.K.; Mitchell, A.J.; Yau, B.; Ball, H.J.; McGregor, I.S.; Hunt, N.H. Interleukin-18 deficiency and its long-term behavioural and cognitive impacts in a murine model of pneumococcal meningitis. Behav. Brain Res. 2014, 263, 176-189.
37. Maes, M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35, 664-175.
38. Raison, C.L.; Dantzer, R.; Kelley, K.W.; Lawson, M.A.; Woolwine, B.J.; Vogt, G.; Spivey, J.R.; Saito, K.; Miller, A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-α: Relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15, 393-403.
39. Filippini, P.; del Papa, N.; Sambataro, D.; del Bufalo, A.; Locatelli, F.; Rutella, S. Emerging concepts on inhibitors of indoleamine 2,3-dioxygenase in rheumatic diseases. Curr. Med. Chem. 2012, 19, 5381-5393.
40. Miller, A.H.; Haroon, E.; Raison, C.L.; Felger, J.C. Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits. Depress. Anxiety 2013, 30, 297-306.
41. Myint, A.M.; Bondy, B.; Baghai, T.C.; Eser, D.; Nothdurfter, C.; Schule, C.; Zill, P.; Muller, N.; Rupprecht, R.; Schwarz, M.J. Tryptophan metabolism and immunogenetics in major depression: A role for interferon-γ gene. Brain Behav. Immun. 2013, 128-133.
42. Chrusciel, M. Changes resembling lupus erythematosus after prolonged treatment with Ro-4-4602, a potent inhibitor of 5-HTP-carboxyliase, in white rats. Eur. J. Pharmacol. 1969, 8, 192-199.
43. Hoyo-Becerra, C.; Schlaak, J.F.; Hermann, D.M. Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation. Brain Behav. Immun. 2014, 42, 222-231.
44. Xiang, Z.Y.; Tang, A.G.; Ren, Y.P.; Zhou, Q.X.; Luo, X.B. Simultaneous determination of serum tryptophan metabolites in patients with systemic lupus erythematosus by high performance liquid chromatography with fluorescence detection. Clin. Chem. Lab. Med. 2010, 48, 513-517.
45. Perkins, M.N.; Stone, T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 1982, 247, 184-187.
46. Perkins, M.N.; Stone, T.W. Pharmacology and regional variations of quinolinic acid-evoked excitations in the rat central nervous system. J. Pharmacol. Exp. Ther. 1983, 226, 551-557.
47. Hughes, P.E.; Alexi, T.; Yoshida, T.; Schreiber, S.S.; Knusel, B. Excitotoxic lesion of rat brain with quinolinic acid induces expression of p53 messenger RNA and protein and p53-inducible genes Bax and Gadd-45 in brain areas showing DNA fragmentation. Neuroscience 1996, 74, 1143-1160.
48. Moresco, R.M.; Lavazza, T.; Belloli, S.; Lecchi, M.; Pezzola, A.; Todde, S.; Matarrese, M.; Carpinelli, A.; Turolla, E.; Zimarino, V.; et al. Quinolinic acid induced neurodegeneration in the striatum: A combined in vivo and in vitro analysis of receptor changes and microglia activation. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 704-715.
49. Velloso, N.A.; Dalmolin, G.D.; Gomes, G.M.; Rubin, M.A.; Canas, P.M.; Cunha, R.A.; Mello, C.F. Spermine improves recognition memory deficit in a rodent model of Huntington’s disease. Neurobiol. Learn. Mem. 2009, 92, 574-580.
50. Dantzer, R.; Walker, A.K. Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression? J. Neural Transm. 2014, 121, 925-932.
51. Shear, D.A.; Dong, J.; Haik-Creguer, K.L.; Bazzett, T.J.; Albin, R.L.; Dunbar, G.L. Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task. Exp. Neurol. 1998, 150, 305-311.
52. Walker, A.K.; Budac, D.P.; Bisulco, S.; Lee, A.W.; Smith, R.A.; Beenders, B.; Kelley, K.W.; Dantzer, R. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013, 38, 1609-1616.
53. Steiner, J.; Walter, M.; Gos, T.; Guillemin, G.J.; Bernstein, H.G.; Sarnyai, Z.; Mawrin, C.; Brisch, R.; Bielau, H.; Meyerzu Schwabedissen, L.; et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission? J. Neuroinflamm. 2011, 8, 94.
54. Stone, T.W.; Perkins, M.N. Quinolinic acid: A potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 1981, 72, 411-412.
55. Schwarcz, R.; Kohler, C. Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci. Lett. 1983, 38, 85-90.
56. Pocivavsek, A.; Wu, H.Q.; Potter, M.C.; Elmer, G.I.; Pellicciari, R.; Schwarcz, R. Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology 2011, 36, 2357-2367.
57. Sakic, B.; Denburg, J.A.; Denburg, S.D.; Szechtman, H. Blunted sensitivity to sucrose in autoimmune MRL-lpr mice: A curve-shift study. Brain Res. Bull. 1996, 41, 305-311.
58. Efthimiou, P.; Blanco, M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod. Rheumatol. 2009, 19, 457-468.
59. Funauchi, M.; Sugishima, H.; Minoda, M.; Horiuchi, A. Serum level of interferon-γ in autoimmune diseases. Tohoku J. Exp. Med. 1991, 164, 259-267.
60. Kwant, A.; Sakic, B. Behavioral effects of infection with interferon-γ adenovector. Behav. Brain Res. 2004, 151, 73-82.
61. Schrott, L.M.; Crnic, L.S. Attenuation of behavioral abnormalities in autoimmune mice by chronic soluble interferon-γ receptor treatment. Brain Behav. Immun. 1998, 12, 90-106.
62. Svenungsson, E.; Andersson, M.; Brundin, L.; van Vollenhoven, R.; Khademi, M.; Tarkowski, A.; Greitz, D.; Dahlstrom, M.; Lundberg, I.; Klareskog, L.; et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann. Rheum. Dis. 2001, 60, 372-379.
63. Blenman, K.R.; Duan, B.; Xu, Z.; Wan, S.; Atkinson, M.A.; Flotte, T.R.; Croker, B.P.; Morel, L. IL-10 regulation of lupus in the NZM2410 murine model. Lab. Investig. 2006, 86, 1136-1148.
64. Chun, H.Y.; Chung, J.W.; Kim, H.A.; Yun, J.M.; Jeon, J.Y.; Ye, Y.M.; Kim, S.H.; Park, H.S.; Suh, C.H. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 2007, 27, 461-466.
65. Rood, M.J.; Keijsers, V.; van der Linden, M.W.; Tong, T.Q.; Borggreve, S.E.; Verweij, C.L.; Breedveld, F.C.; Huizinga, T.W. Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann. Rheum. Dis. 1999, 58, 85-89.
66. Tian, G.; Li, J.L.; Wang, D.G.; Zhou, D. Targeting IL-10 in auto-immune diseases. Cell Biochem. Biophys. 2014, 70, 37-49.
67. Yin, Z.; Bahtiyar, G.; Zhang, N.; Liu, L.; Zhu, P.; Robert, M.E.; McNiff, J.; Madaio, M.P.; Craft, J. IL-10 regulates murine lupus. J. Immunol. 2002, 169, 2148-2155.
68. Talaat, R.M.; Mohamed, S.F.; Bassyouni, I.H.; Raouf, A.A. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine 2015, 72, 146-153.
69. Elia, G. Interferon-γ-Inducible chemokines in Systemic Lupus Erythematosus. Clin. Ther. 2015, 166, e41-e46.
70. Kong, K.O.; Tan, A.W.; Thong, B.Y.; Lian, T.Y.; Cheng, Y.K.; Teh, C.L.; Koh, E.T.; Chng, H.H.; Law, W.G.; Lau, T.C.; et al. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin. Exp. Immunol. 2009, 156, 134-140.
71. Lu, X.Y.; Zhu, C.Q.; Qian, J.; Chen, X.X.; Ye, S.; Gu, Y.Y. Intrathecal cytokine and chemokine profiling in neuropsychiatric lupus or lupus complicated with central nervous system infection. Lupus 2010, 19, 689-695.
72. Okamoto, H.; Iikuni, N.; Kamitsuji, S.; Yoshio, T.; Minota, S.; Kamatani, N. IP-10/MCP-1 ratio in CSF is an useful diagnostic marker of neuropsychiatric lupus patients. Rheumatology 2006, 45, 232-234.
73. Santer, D.M.; Yoshio, T.; Minota, S.; Moller, T.; Elkon, K.B. Potent induction of IFN-α and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J. Immunol. 2009, 182, 1192-1201.
74. Bauer, J.W.; Petri, M.; Batliwalla, F.M.; Koeuth, T.; Wilson, J.; Slattery, C.; Panoskaltsis-Mortari, A.; Gregersen, P.K.; Behrens, T.W.; Baechler, E.C. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis Rheum. 2009, 60, 3098-3107.
75. Cieslik, P.; Hrycek, A. Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus. Autoimmunity 2014, 48, 1-9.
76. Iikuni, N.; Okamoto, H.; Yoshio, T.; Sato, E.; Kamitsuji, S.; Iwamoto, T.; Momohara, S.; Taniguchi, A.; Yamanaka, H.; Minota, S.; et al. Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus. Ann. Rheum. Dis. 2006, 65, 253-256.
77. Shah, D.; Wanchu, A.; Bhatnagar, A. Interaction between oxidative stress and chemokines: Possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology 2011, 216, 1010-1017.
78. Singh, S.; Wu, T.; Xie, C.; Vanarsa, K.; Han, J.; Mahajan, T.; Oei, H.B.; Ahn, C.; Zhou, X.J.; Putterman, C.; et al. Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. Arthritis Res. Ther. 2012, 14, R164.
79. Zameer, A.; Hoffman, S.A. Increased ICAM-1 and VCAM-1 expression in the brains of autoimmune mice. J. Neuroimmunol. 2003, 142, 67-74.
80. Pavon, E.J.; Munoz, P.; Lario, A.; Longobardo, V.; Carrascal, M.; Abian, J.; Martin, A.B.; Arias, S.A.; Callejas-Rubio, J.L.; Sola, R.; et al. Proteomic analysis of plasma from patients with systemic lupus erythematosus: Increased presence of haptoglobin α2 polypeptide chains over the α1 isoforms. Proteomics 2006, 6, S282-S292.
81. Finklestein, S.P.; Fanning, P.J.; Caday, C.G.; Powell, P.P.; Foster, J.; Clifford, E.M.; Klagsbrun, M. Increased levels of basic fibroblast growth factor (bFGF) following focal brain injury. Restor. Neurol. Neurosci. 1990, 1, 387-394.
82. Gospodarowicz, D.; Neufeld, G.; Schweigerer, L. Fibroblast growth factor: Structural and biological properties. J. Cell. Physiol. 1987, 5, 15-26.
83. Finklestein, S.P.; Apostolides, P.J.; Caday, C.G.; Prosser, J.; Philips, M.F.; Klagsbrun, M. Increased basic fibroblast growth factor (bFGF) immunoreactivity at the site of focal brain wounds. Brain Res. 1988, 460, 253-259.
84. House, S.L.; Bolte, C.; Zhou, M.; Doetschman, T.; Klevitsky, R.; Newman, G.; Schultz Jel, J. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 2003, 108, 3140-3148.
85. Schweigerer, L.; Neufeld, G.; Friedman, J.; Abraham, J.A.; Fiddes, J.C.; Gospodarowicz, D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987, 325, 257-259.
86. Carlin, J.M.; Borden, E.C.; Sondel, P.M.; Byrne, G.I. Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J. Immunol. 1987, 139, 2414-2418.
87. Yasui, H.; Takai, K.; Yoshida, R.; Hayaishi, O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: Its possible occurrence in cancer patients. Proc. Natl. Acad. Sci. USA 1986, 83, 6622-6626.
88. Maes, M.; Leonard, B.E.; Myint, A.M.; Kubera, M.; Verkerk, R. The new ‘5-HT’ hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35, 702-721.
89. Munn, D.H.; Sharma, M.D.; Lee, J.R.; Jhaver, K.G.; Johnson, T.S.; Keskin, D.B.; Marshall, B.; Chandler, P.; Antonia, S.J.; Burgess, R.; et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297, 1867-1870.
90. Yanagawa, Y.; Iwabuchi, K.; Onoe, K. Co-operative action of interleukin-10 and interferon-γ to regulate dendritic cell functions. Immunology 2009, 127, 345-353.
91. Odemuyiwa, S.O.; Ghahary, A.; Li, Y.; Puttagunta, L.; Lee, J.E.; Musat-Marcu, S.; Ghahary, A.; Moqbel, R. Cutting edge: Human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J. Immunol. 2004, 173, 5909-5913.
92. Munn, D.H.; Shafizadeh, E.; Attwood, J.T.; Bondarev, I.; Pashine, A.; Mellor, A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999, 189, 1363-1372.
93. Mellor, A.L.; Munn, D.H. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4, 762-774.
94. Chess, A.C.; Simoni, M.K.; Alling, T.E.; Bucci, D.J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull. 2007, 33, 797-804.
95. Kozak, R.; Campbell, B.M.; Strick, C.A.; Horner, W.; Hoffmann, W.E.; Kiss, T.; Chapin, D.S.; McGinnis, D.; Abbott, A.L.; Roberts, B.M.; et al. Reduction of brain kynurenic acid improves cognitive function. J. Neurosci. 2014, 34, 10592-10602.
96. Van Wetering, S.; van den Berk, N.; van Buul, J.D.; Mul, F.P.; Lommerse, I.; Mous, R.; ten Klooster, J.P.; Zwaginga, J.J.; Hordijk, P.L. VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration. Am. J. Physiol. Cell Physiol. 2003, 285, C343-C352.
97. Dimitrijevic, O.B.; Stamatovic, S.M.; Keep, R.F.; Andjelkovic, A.V. Effects of the chemokine CCL2 on blood-brain barrier permeability during ischemia-reperfusion injury. J. Cereb. Blood Flow Metab. 2006, 26, 797-810.
98. Chai, Q.; She, R.; Huang, Y.; Fu, Z.F. Expression of neuronal CXCL10 induced by rabies virus infection initiates infiltration of inflammatory cells, production of chemokines and cytokines, and enhancement of blood-brain barrier permeability. J. Virol. 2015, 89, 870-876.
99. Brew, B.J.; Letendre, S.L. Biomarkers of HIV related central nervous system disease. Int. Rev. Psychiatry 2008, 20, 73-88.
100. Westin, K.; Buchhave, P.; Nielsen, H.; Minthon, L.; Janciauskiene, S.; Hansson, O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease. PLoS ONE 2012, 7, e30525.
101. Chiarugi, A.; Meli, E.; Moroni, F. Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J. Neurochem. 2001, 77, 1310-1318.
102. Eastman, C.L.; Guilarte, T.R. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem. Res. 1990, 15, 1101-1107.
103. Okuda, S.; Nishiyama, N.; Saito, H.; Katsuki, H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem. 1998, 70, 299-307.
104. Plangar, I.; Majlath, Z.; Vecsei, L. Kynurenines in cognitive functions: Their possible role in depression. Neuropsychopharmacol. Hung. 2012, 14, 239-244.
105. Capuron, L.; Neurauter, G.; Musselman, D.L.; Lawson, D.H.; Nemeroff, C.B.; Fuchs, D.; Miller, A.H. Interferon-α-induced changes in tryptophan metabolism: Relationship to depression and paroxetine treatment. Biol. Psychiatry 2003, 54, 906-914.
106. Vogelgesang, S.A.; Heyes, M.P.; West, S.G.; Salazar, A.M.; Sfikakis, P.P.; Lipnick, R.N.; Klipple, G.L.; Tsokos, G.C. Quinolinic acid in patients with systemic lupus erythematosus and neuropsychiatric manifestations. J. Rheumatol. 1996, 23, 850-855.
107. Ennaceur, A.; Meliani, K. A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs. non-spatial working memory. Behav. Brain Res. 1992, 51, 83-92.
108. Aggleton, J.P.; Albasser, M.M.; Aggleton, D.J.; Poirier, G.L.; Pearce, J.M. Lesions of the rat perirhinal cortex spare the acquisition of a complex configural visual discrimination yet impair object recognition. Behav. Neurosci. 2010, 124, 55-68.
109. Albasser, M.M.; Davies, M.; Futter, J.E.; Aggleton, J.P. Magnitude of the object recognition deficit associated with perirhinal cortex damage in rats: Effects of varying the lesion extent and the duration of the sample period. Behav. Neurosci. 2009, 123, 115-124.
110. Belarbi, K.; Jopson, T.; Tweedie, D.; Arellano, C.; Luo, W.; Greig, N.H.; Rosi, S. TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J. Neuroinflamm. 2012, 9, 23.
111. Chitu, V.; Gokhan, S.; Gulinello, M.; Branch, C.A.; Patil, M.; Basu, R.; Stoddart, C.; Mehler, M.F.; Stanley, E.R. Phenotypic characterization of a Csf1r haploinsufficient mouse model of adult-onset leukodystrophy with axonal spheroids and pigmented glia (ALSP). Neurobiol. Dis. 2015, 74, 219-228.
112. Cole, P.D.; Vijayanathan, V.; Ali, N.F.; Wagshul, M.E.; Tanenbaum, E.J.; Price, J.; Dalal, V.; Gulinello, M.E. Memantine protects rats treated with intrathecal methotrexate from developing spatial memory deficits. Clin. Cancer Res. 2013, 19, 4446-4454.
113. Li, Y.; Vijayanathan, V.; Gulinello, M.; Cole, P.D. Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine. Pharmacol. Biochem. Behav. 2010, 95, 428-433.
114. Li, Y.; Vijayanathan, V.; Gulinello, M.E.; Cole, P.D. Systemic methotrexate induces spatial memory deficits and depletes cerebrospinal fluid folate in rats. Pharmacol. Biochem. Behav. 2010, 94, 454-463.
115. Vijayanathan, V.; Gulinello, M.; Ali, N.; Cole, P.D. Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist. Behav. Brain Res. 2011, 225, 491-497.
116. Ennaceur, A.; Delacour, J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav. Brain Res. 1988, 31, 47-59.
117. Bodnoff, S.R.; Suranyi-Cadotte, B.; Quirion, R.; Meaney, M.J. A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology 1989, 97, 277-279.
118. Pellow, S.; File, S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 1986, 24, 525-529.
119. Porsolt, R.D. Animal model of depression. Biomedicine 1979, 30, 139-140.
120. Porsolt, R.D.; Bertin, A.; Jalfre, M. “Behavioural despair” in rats and mice: Strain differences and the effects of imipramine. Eur. J. Pharmacol. 1978, 51, 291-294.